多发性骨髓瘤细胞XG-7诱导CD8和TCRαβ阳性的T细胞增殖分化成为细胞毒效应细胞

Multiple Myeloma Cell Line XG-7 Can Induce CD8 +TCRαβ-bearing T Cell to Proliferate and Differentiate into Cytotoxic Effector Cells

采用经密度梯度离心获得的正常健康人外周血淋巴细胞 (PBL )与多发性骨髓瘤细胞XG 7进行混合肿瘤淋巴细胞培养。3 H TdR掺入实验证实XG 7细胞可刺激PBL增殖 ;间接免疫荧光检测显示增殖的PBL中 ,CD4+ /CD8+ 细胞比例偏移 ,CD8+ T细胞增加。激活的CD8+ T细胞在含IL 2的培养体系中得到迅速扩增 ,占细胞总数的 96 %以上。流式细胞仪检测显示 ,扩增的T细胞表达CD3,CD8和TCRαβ ,而不表达CD4,CD16和CD5 6。细胞毒实验结果表明 ,扩增的CD8+ T细胞不仅杀伤原刺激细胞XG 7,也可杀伤其它肿瘤细胞如RPMI82 2 6 ,U2 6 6和Daudi。上述结果说明了经XG 7细胞所刺激PBL中的CD8+ T细胞可增殖分化成为抗肿瘤细胞的细胞毒效应细胞 ,这使得它们有可能在临床上用于肿瘤病人的治疗。

In the present study,the peripheral blood lymphocytes (PBL) from healthy donors were obtained after Ficoll Hypaque centrifugation and co cultured with the multiple myeloma cell line XG 7 An 3 H TdR incorporation assay demonstrated that PBL proliferated well in response to XG 7 stimulation An immunofluorescence assay showed that the CD4 +/CD8 + ratio was skewed and the proportion of CD8 + T cells increased The activated CD8 + T cell population could be rapidly amplified in the IL 2 containing culture system and accounted for more than 96 percent of total cells Cytometry was used to assess the phenotype of the amplified T cells and the results revealed that the molecules CD3,CD8 and TCRαβ,were detectable,but not for CD4,CD16 and CD56 Cytotoxicity experiments perfomed with amplified CD8 + T cells showed that they could lyse not only the original stimulator XG 7 cells,but also other tumor cells such as RPMI8226,U266 and Daudi In summary,the above results indicate that CD8 + T cells in PBL after stimulation by XG 7 cells can proliferate and differentiate into cytotoxic effector cells against tumor cells This may potentially be useful in clinic for treatment of tumor patients